Melanotan II Pricing: April 2026

Melanotan II (MT-II) is a synthetic broad-spectrum melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R) used for skin tanning, libido enhancement, and appetite suppression. Often confused with PT-141 (bremelanotide), the two differ substantially: MT-II's broader receptor activity drives tanning via MC1R, while PT-141 is MC3R/MC4R selective and affects only sexual function.

Regulatory status (April 2026): MT-II is NOT FDA-approved and remains on the FDA's Category 2 list. In the February 2026 HHS announcement, most peptides were moved off Category 2 — but MT-II was specifically excluded due to melanoma/skin cancer concerns (MC1R agonism can drive pigmentation in existing nevi), cardiovascular stress, and insufficient human safety data.

This creates a sharp contrast with PT-141:

• No FDA-approved branded version exists for MT-II (vs. Vyleesi for PT-141)
• No legal compounding under 503A or 503B pathways (vs. PT-141, widely compounded)
• No telehealth platforms legally prescribe it — all legitimate access channels are closed
• FDA issued 14 warning letters to consumer suppliers in 2026
• Illegal to sell in all 50 US states, UK, and Australia (reclassified Schedule 9 in Feb 2026)

The only available pricing is from gray-market research chemical vendors labeling products "not for human consumption." Standard dosing: Loading at 0.25 mg (250 mcg) subcutaneous daily for 1–2 weeks, then 0.5–1 mg 1–2x/week maintenance. Available as injectable lyophilized powder (most common) or nasal spray (10 mg per 10 mL bottle typical).

Common side effects: Nausea, facial flushing, darkening of existing moles, spontaneous erections in men. Insurance does not cover MT-II.